Please login to the form below
pneumococcal conjugate vaccine
This page shows the latest pneumococcal conjugate vaccine news and features for those working in and with pharma, biotech and healthcare.
MSD’s Vaxneuvance approved by MHRA for prevention of pneumococcal diseases in children
As the first new pneumococcal conjugate vaccine (PCV) in over a decade, we hope to see the new generation of pneumococcal vaccines assessed holistically by the UK health system,” Herath added. ... a catch-up setting for older children who are either
Latest news
-
Pfizer to evaluate its pneumococcal vaccine alongside COVID-19 booster jab
Pfizer has launched a new study of its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) along with a booster dose of its BioNTech-partnered COVID-19 jab. ... 20vPnC includes capsular polysaccharide conjugates for the 13 serotypes in Pfizer’s
-
Merck wins speedy FDA review for 15-valent pneumococcal vaccine
Merck &Co (MSD) has been given a fast-track designation for its next-generation 15-valent pneumococcal conjugate vaccine candidate V114. ... If approved, Merck’s V114 will be a close competitor of Pfizer's Prevnar-13, although Pfizer is seeking to
-
Merck submits 15-valent pneumococcal vaccine candidate to EMA and FDA
its 15-valent pneumococcal conjugate vaccine candidate V114. ... For more than a century, Merck inventors have developed vaccines that help tackle some of society’s biggest public health challenges, and that heritage is reflected today in our
-
Pfizer eyes 20-strain Prevnar filing this year, after phase 3 win
New-generation shot could protect franchise from rival Merck &Co. Pfizer says it could be on course to file for approval of its new generation pneumococcal conjugate vaccine in the US ... Merck is hoping to muscle into Prevnar 13’s position in
-
Pfizer’s Prevnar-13 successor takes aim at Merck rival
Rivals look to broaden coverage across strains. Pfizer just got a leg-up in its race with Merck &Co to bring a new-generation pneumococcal vaccine to the US market after ... continue to build on our expertise in pneumococcal conjugate vaccines with this
More from news
Approximately 1 fully matching, plus 14 partially matching documents found.
Latest Intelligence
-
Deal Watch table for March 2014
26.6. ‡SK Chemicals/ Sanofi Pasteur. Collaboration. Pneumococcal conjugate vaccine (PCV). 23.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- Europe’s cancer community publishes new report on transforming patient care
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- EU outlines measures to mitigate antibiotic shortage across Europe
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Merging global and local pharmacovigilance operations into a successful integrated approach
PMHub
BOLDSCIENCE
We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
